FDA Clears Extended-Release Tofacitinib (Xeljanz XR) for RAFDA Clears Extended-Release Tofacitinib (Xeljanz XR) for RA

Xeljanz XR provides a once-daily oral option for patients with moderate to severe rheumatoid arthritis. FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news